ClinicalTrials.Veeva

Menu
S

Skin Care Physicians of Georgia | Macon, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Apremilast
CC-10004
Dupilumab
Baricitinib
LY3009104
Guselkumab
JNJ-77242113
Lebrikizumab
RPT193
Ixekizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 22 total trials

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue...

Active, not recruiting
Psoriasis
Drug: Apremilast

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the...

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO.This is a master protocol whic...

Enrolling
Pruritus
Drug: Placebo
Drug: Dupilumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

Trial sponsors

Lilly logo
Amgen logo
BTL logo
Janssen (J&J Innovative Medicine) logo
Sanofi logo
AbbVie logo
A
Pfizer logo
RAPT Therapeutics logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems